Nerymar Ortiz-Otero1, Jocelyn R Marshall1, Antonio Glenn2, Jubin Matloubieh3, Jean Joseph3, Deepak M Sahasrabudhe3, Edward M Messing3, Michael R King4. 1. Meinig School of Biomedical Engineering, Cornell University, Ithaca, NY, 14850, USA. 2. Department of Biomedical Engineering, Vanderbilt University, Nashville, TN, 37202, USA. 3. The University of Rochester Medical Center, Rochester, NY, 14642, USA. 4. Department of Biomedical Engineering, Vanderbilt University, Nashville, TN, 37202, USA. mike.king@vanderbilt.edu.
Abstract
BACKGROUND: Radical surgery is the first line treatment for localized prostate cancer (PC), however, several studies have demonstrated that surgical procedures induce tumor cell mobilization from the primary tumor into the bloodstream. METHODS: The number and temporal fluctuations of circulating tumor cells (CTC), cancer associated fibroblasts (CAF) and CTC cluster present in each blood sample was determined. RESULTS: The results show that both CTC and CTC cluster levels significantly increased immediately following primary tumor resection, but returned to baseline within 2 weeks post-surgery. In contrast, the CAF level decreased over time. In patients who experienced PC recurrence within months after resection, CTC, CAF, and cluster levels all increased over time. Based on this observation, we tested the efficacy of an experimental TNF-related apoptosis-inducing ligand (TRAIL)-based liposomal therapy ex-vivo to induce apoptosis in CTC in blood. The TRAIL-based therapy killed approximately 75% of single CTCs and CTC in cluster form. CONCLUSION: Collectively, these data indicate that CTC cluster and CAF levels can be used as a predictive biomarker for cancer recurrence. Moreover, for the first time, we demonstrate the efficacy of our TRAIL-based liposomal therapy to target and kill prostate CTC in primary patient blood samples, suggesting a potential new adjuvant therapy to use in combination with surgery.
BACKGROUND: Radical surgery is the first line treatment for localized prostate cancer (PC), however, several studies have demonstrated that surgical procedures induce tumor cell mobilization from the primary tumor into the bloodstream. METHODS: The number and temporal fluctuations of circulating tumor cells (CTC), cancer associated fibroblasts (CAF) and CTC cluster present in each blood sample was determined. RESULTS: The results show that both CTC and CTC cluster levels significantly increased immediately following primary tumor resection, but returned to baseline within 2 weeks post-surgery. In contrast, the CAF level decreased over time. In patients who experienced PC recurrence within months after resection, CTC, CAF, and cluster levels all increased over time. Based on this observation, we tested the efficacy of an experimental TNF-related apoptosis-inducing ligand (TRAIL)-based liposomal therapy ex-vivo to induce apoptosis in CTC in blood. The TRAIL-based therapy killed approximately 75% of single CTCs and CTC in cluster form. CONCLUSION: Collectively, these data indicate that CTC cluster and CAF levels can be used as a predictive biomarker for cancer recurrence. Moreover, for the first time, we demonstrate the efficacy of our TRAIL-based liposomal therapy to target and kill prostate CTC in primary patient blood samples, suggesting a potential new adjuvant therapy to use in combination with surgery.
Authors: Urszula M Domanska; Jennifer C Boer; Hetty Timmer-Bosscha; Marcel A T M van Vugt; Hilde D Hoving; Nathalie M Kliphuis; Stefano Rosati; Henk G van der Poel; Igle Jan de Jong; Elisabeth G E de Vries; Annemiek M E Walenkamp Journal: Clin Exp Metastasis Date: 2014-08-26 Impact factor: 5.150
Authors: Dan G Duda; Annique M M J Duyverman; Mitsutomo Kohno; Matija Snuderl; Ernst J A Steller; Dai Fukumura; Rakesh K Jain Journal: Proc Natl Acad Sci U S A Date: 2010-11-22 Impact factor: 11.205
Authors: Michael J Mitchell; Elizabeth Wayne; Kuldeepsinh Rana; Chris B Schaffer; Michael R King Journal: Proc Natl Acad Sci U S A Date: 2014-01-06 Impact factor: 11.205
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702
Authors: Nicola Aceto; Aditya Bardia; David T Miyamoto; Maria C Donaldson; Ben S Wittner; Joel A Spencer; Min Yu; Adam Pely; Amanda Engstrom; Huili Zhu; Brian W Brannigan; Ravi Kapur; Shannon L Stott; Toshi Shioda; Sridhar Ramaswamy; David T Ting; Charles P Lin; Mehmet Toner; Daniel A Haber; Shyamala Maheswaran Journal: Cell Date: 2014-08-28 Impact factor: 41.582